| NCT06809179 | A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder | RECRUITING | PHASE2 | 2025-01-09 | 2026-12 | 2026-04 |
| NCT06615557 | Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4) | RECRUITING | PHASE3 | 2024-09-16 | 2026-10 | 2026-04 |
| NCT06358651 | Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3) | RECRUITING | PHASE3 | 2024-03-28 | 2026-06 | 2025-10 |
| NCT04147949 | AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesia | UNKNOWN | PHASE2 | 2022-08 | 2024-04 | 2023-12 |
| NCT05280054 | AV-101 Alone and in Combination With Probenecid in Healthy Subjects | UNKNOWN | PHASE1 | 2021-12-23 | 2022-11-01 | 2022-09-01 |
| NCT04404192 | PH94B in the Treatment of Adjustment Disorder With Anxiety | COMPLETED | PHASE2 | 2021-10-12 | 2022-12-14 | 2022-12-14 |
| NCT05030350 | Open-label Safety Trial of PH94B in Social Anxiety Disorder (SAD) | TERMINATED | PHASE3 | 2021-10-01 | 2022-09-23 | 2022-09-23 |
| NCT05011396 | PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge - 2 | TERMINATED | PHASE3 | 2021-08-30 | 2022-08-16 | 2022-08-16 |
| NCT04754802 | PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge | COMPLETED | PHASE3 | 2021-05-24 | 2022-06-22 | 2022-06-22 |
| NCT03078322 | AV-101 as Adjunct Antidepressant Therapy in Patients With Major Depression | COMPLETED | PHASE2 | 2018-03-05 | 2019-10-01 | 2019-10-01 |
| NCT01483846 | Safety, Tolerability and Pharmacokinetics of Multiple Doses of AV-101 in Healthy Volunteers | COMPLETED | PHASE1 | 2011-12 | 2012-09 | 2012-09 |